Full Name
Nancy Lurker
Job Title
Executive Vice Chair
Company
EyePoint Pharmaceuticals
Speaker Bio
-
As Executive Vice Chair and formerly President and Chief Executive Officer, Nancy leads EyePoint Pharmaceuticals in its mission to improve the lives of people facing serious eye disorders. During her more than 30 years in the pharmaceutical industry, Ms. Lurker has driven scientific and commercial innovation working with both public and private companies from start-ups to the Fortune 500 to bring innovative therapies and diagnostic solutions to patients.
Prior to joining EyePoint in 2016, Ms. Lurker was President and CEO and Board Director of PDI, Inc., a NASDAQ-listed healthcare commercialization company which sold to Publicis Health. Before joining PDI, she was Senior Vice President and Chief Marketing Officer at Novartis Pharmaceuticals. She also served as President and CEO of ImpactRx, Inc., a privately held healthcare information company. Prior to ImpactRx, Ms. Lurker was Group VP, Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career as a Senior Medical Representative at Bristol Myers Squibb, where she quickly rose to Senior Director of Worldwide Cardiovascular Franchise Management, overseeing numerous successful drug launches.
Ms. Lurker currently serves on the Board of Directors of Eyepoint Pharmaceuticals, Altasciences, and Aquestive Therapeutics; as a member of the Novo Holdings Advisory Board; and on the Stanford School of Medicine Masters in Translational Medicine Advisory Board. She has previously held positions on the Boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, Conjuchem, and ImpactRx.
Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. Dedicating her career to maximizing the potential of science to improve the lives of patients, Ms. Lurker is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.
Key boards: Eyepoint Pharmaceuticals (NASDAQ: EYPT), Altasciences, Aquestive Therapeutics (NASDAQ: AQST)
As Executive Vice Chair and formerly President and Chief Executive Officer, Nancy leads EyePoint Pharmaceuticals in its mission to improve the lives of people facing serious eye disorders. During her more than 30 years in the pharmaceutical industry, Ms. Lurker has driven scientific and commercial innovation working with both public and private companies from start-ups to the Fortune 500 to bring innovative therapies and diagnostic solutions to patients.
Prior to joining EyePoint in 2016, Ms. Lurker was President and CEO and Board Director of PDI, Inc., a NASDAQ-listed healthcare commercialization company which sold to Publicis Health. Before joining PDI, she was Senior Vice President and Chief Marketing Officer at Novartis Pharmaceuticals. She also served as President and CEO of ImpactRx, Inc., a privately held healthcare information company. Prior to ImpactRx, Ms. Lurker was Group VP, Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career as a Senior Medical Representative at Bristol Myers Squibb, where she quickly rose to Senior Director of Worldwide Cardiovascular Franchise Management, overseeing numerous successful drug launches.
Ms. Lurker currently serves on the Board of Directors of Eyepoint Pharmaceuticals, Altasciences, and Aquestive Therapeutics; as a member of the Novo Holdings Advisory Board; and on the Stanford School of Medicine Masters in Translational Medicine Advisory Board. She has previously held positions on the Boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, Conjuchem, and ImpactRx.
Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. Dedicating her career to maximizing the potential of science to improve the lives of patients, Ms. Lurker is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.
Key boards: Eyepoint Pharmaceuticals (NASDAQ: EYPT), Altasciences, Aquestive Therapeutics (NASDAQ: AQST)
Speaking At
